Used primarily in pharmaceutical research as a key intermediate in the synthesis of bioactive molecules. Its structure supports the development of compounds with central nervous system activity, particularly in the design of histamine H3 receptor antagonists. The diphenylmethyl group enhances lipophilicity and blood-brain barrier penetration, making it valuable in neuropharmacology. Additionally, the difluoroazetidine moiety contributes to metabolic stability and improved pharmacokinetic profiles in drug candidates. It is also explored in the development of enzyme inhibitors and receptor modulators for treating neurological disorders such as narcolepsy, epilepsy, and cognitive impairments.